ABL1 and hepatocellular carcinoma: Dasatinib binds to >30 kinases56 and has been shown to inhibit57 multiple tyrosine kinases of the ABL, DDR, TEC (tyrosine kinase expressed in hepatocellular carcinoma), SRC (sarcoma kinase) and EPH subfamilies at low nM concentrations.